Precision Medicine

Oncologist and commentator Vinay Prasad has published a piece arguing that celebrated mathematician Terence Tao does not understand cancer medicine. The post, on Prasad's Substack, is being discussed on Hacker News, where it has drawn modest engagement so far. The precise remarks by Tao that prompted the criticism are not detailed in the available evidence, and Tao has not responded.

A discussion published by Dermatology Times examines how precision medicine is being applied to atopic dermatitis and skin cancers, arguing that tailored therapies based on individual patient profiles can improve outcomes in these conditions. The piece highlights the growing role of targeted treatments in dermatology, where biologic therapies and molecular diagnostics are increasingly shaping care decisions for chronic inflammatory skin disease and skin malignancies.

A newly published review examines non-nutritional rickets, a group of rare bone-softening disorders caused by genetic or metabolic factors rather than vitamin D deficiency. The paper covers diagnostic approaches, the role of precision medicine in tailoring treatment to underlying causes, and reported patient outcomes. It is aimed at clinicians managing these uncommon conditions, where standard vitamin D supplementation is not effective.

Inside Precision Medicine has published the second part of its Reporter's Notebook series arguing that cell and gene therapy will only achieve lasting success if the field moves beyond bespoke, patient-by-patient treatments toward scalable, standardized approaches. The piece examines what industrializing these advanced therapies would mean for developers, manufacturers and patients as the sector matures.

Experts are weighing what precision medicine should actually mean for multiple sclerosis care, moving beyond the label toward individualized treatment selection based on disease biology, biomarkers and patient characteristics. The discussion reflects a broader push in neurology to tailor disease-modifying therapies rather than rely on a one-size-fits-all approach, though consensus on a clear definition and clinical implementation remains limited.

Medical industry commentary is asking how biomarker-led diagnostics will reshape respiratory medicine, amid growing interest in tests that could detect and monitor lung conditions earlier and more precisely. The discussion, surfacing through pharmaceutical trade coverage, focuses on whether biological markers can move respiratory care beyond symptom-based diagnosis toward personalised treatment.

Inside Precision Medicine has published a Reporter's Notebook arguing that the long-term success of cell and gene therapy depends on moving beyond individually tailored, bespoke treatments. The piece, the first in a series, examines how the field can scale therapies designed for one patient at a time into broader, more accessible approaches, a central challenge for biotech companies and health systems.

Medical commentators are discussing what precision medicine should mean for multiple sclerosis care, focusing on how treatments can be tailored to individual patients based on disease course, biomarkers, and response profiles. The conversation reflects ongoing debate in the neurology field about moving away from one-size-fits-all therapy and toward personalized treatment strategies for people living with MS.

A new market report projects steady expansion of the digital real-time PCR systems market through 2035, driven largely by the rise of precision medicine and growing demand for advanced diagnostics. The analysis points to continued investment in molecular testing technologies as healthcare systems shift toward more personalised, data-driven treatment and earlier disease detection.

Luis Chia has been appointed Senior Director of Global Commercial Development at Revolution Medicines, the California-based oncology company developing targeted cancer therapies. The announcement was reported by Oncodaily. The move signals the company's continued build-out of its commercial team as it advances its pipeline of precision medicines toward broader market readiness.

German biophysicist Georg Nagel is being discussed in connection with the Nobel Prize in Medicine, thanks to his pioneering work on optogenetics, a technique that uses light-sensitive proteins to switch nerve cells on and off. The method has revolutionised brain research, allowing scientists to precisely control neurons in living tissue. German media are revisiting how the 'light switch' discovery reshaped neuroscience and why Nagel's contribution remains central to the debate over who deserves the honour.

A new market forecast projects steady growth for rapid sequencing kits through 2035, driven mainly by rising demand for infectious disease diagnostics and the expansion of precision medicine. The report points to faster pathogen identification and tailored treatment approaches as the key factors pulling laboratories and hospitals toward rapid sequencing technologies over the coming decade.

New market research projects growth in the rapid sequencing kits market through 2035, driven largely by demand from infectious disease diagnostics and the expansion of precision medicine. Faster genome sequencing has become central to identifying pathogens quickly and tailoring treatments to individual patients, and industry analysts expect both sectors to keep fuelling demand for rapid kit technologies over the next decade.

A startup called Arboretum has launched, aiming to apply precision medicine approaches to common diseases rather than rare conditions. The company's emergence signals growing interest in tailoring treatments to individual patient profiles across widespread illnesses such as diabetes and heart disease. Details on funding, leadership and its therapeutic focus remain limited, and reaction from the medical and investment communities has yet to become visible.

A systematic review published in Nature examines how precision medicine may widen or reflect existing health inequalities. The review consolidates evidence on unequal access to genetic testing, targeted therapies and genomic research participation, with disadvantaged groups underrepresented. Researchers and health policy commentators are citing it in ongoing debates about equity in genomics-driven healthcare and who benefits from personalised treatment advances.

A review published in Frontiers examines how chronic spontaneous urticaria could move beyond disease activity scores toward precision medicine. It looks at biomarkers and composite models that might help clinicians stratify patients by risk, predict disease course and tailor treatment. The work reflects a broader push in immunology to personalise management of chronic inflammatory skin conditions.

The International Atomic Energy Agency is hosting a global symposium on dosimetry in Vienna, bringing together specialists to discuss precision in radiation medicine. The event focuses on improving accuracy in measuring radiation doses for cancer treatment and diagnosis, a key factor in patient safety and treatment effectiveness. Experts from around the world are expected to exchange best practices and advances in the field.

Five precision medicines are awaiting US regulatory decisions in the final quarter of 2026, with the FDA set to rule on each targeted therapy in the coming months. The roundup tracks expected approval deadlines for treatments designed against specific genetic profiles. Observers in oncology and rare disease circles are watching the outcomes for signals on how the agency is handling genetically targeted drugs.

ElevateBio is drawing attention with a detailed look at the technologies it uses to engineer precision genetic medicines. The company, which builds cell and gene therapies and supplies the underlying tech to partners, is showcasing its suite of tools for editing and manufacturing genomic medicines. Industry observers see it as part of the broader push to make genetic medicine production more reliable and scalable.

Matt Begemann is being featured for work on a CRISPR-based approach aimed at killing cancer cells, according to Inside Precision Medicine. The item highlights how gene-editing technology is being explored as a direct weapon against cancer, a topic that continues to draw attention as CRISPR therapies move from laboratory research toward clinical use in precision medicine.

Vanderbilt Health researchers have led a new scientific statement outlining opportunities to advance precision kidney medicine for women. The statement highlights gaps in how kidney disease is understood and treated in female patients and calls for more tailored, sex-specific approaches to diagnosis and care. It is drawing attention among clinicians and researchers focused on women's health and nephrology.

Coverage of day four of the EADV 2026 congress highlights discussions on precision medicine and the use of real-world evidence to shape the future of dermatologic care. Dermatology specialists and commentators are weighing how personalized treatment approaches and data from everyday clinical practice could change how skin conditions are diagnosed and managed going forward.